Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308957608> ?p ?o ?g. }
- W4308957608 abstract "Cancer is one of the leading causes of death across the world, and the prevalence and mortality rates of cancer will continue to grow. Chemotherapeutics play a critical role in cancer therapy, but drug resistance and side effects are major hurdles to effective treatment, evoking an immediate need for the discovery of new anticancer agents. Triazines including 1,2,3-, 1,2,4-, and 1,3,5-triazine have occupied a propitious place in drug design and development due to their excellent pharmacological profiles. Mechanistically, triazine derivatives could interfere with various signaling pathways to induce cancer cell death. Hence, triazine derivatives possess potential in vitro and in vivo efficacy against diverse cancers. In particular, triazine hybrids are able to overcome drug resistance and reduce side effects. Moreover, several triazine hybrids such as brivanib (indole-containing pyrrolo[2,1-f][1,2,4]triazine), gedatolisib (1,3,5-triazine-urea hybrid), and enasidenib (1,3,5-triazine-pyridine hybrid) have already been available in the market. Accordingly, triazine hybrids are useful scaffolds for the discovery of novel anticancer chemotherapeutics. This review focuses on the anticancer activity of 1,2,3-, 1,2,4-, and 1,3,5-triazine hybrids, together with the structure-activity relationships and mechanisms of action developed from 2017 to the present. The enriched structure-activity relationships may be useful for further rational drug development of triazine hybrids as potential clinical candidates." @default.
- W4308957608 created "2022-11-20" @default.
- W4308957608 creator A5003177727 @default.
- W4308957608 creator A5005515791 @default.
- W4308957608 creator A5030477809 @default.
- W4308957608 creator A5039605863 @default.
- W4308957608 creator A5052274720 @default.
- W4308957608 creator A5081534229 @default.
- W4308957608 date "2022-11-13" @default.
- W4308957608 modified "2023-10-14" @default.
- W4308957608 title "Recent updates on 1,2,3‐, 1,2,4‐, and 1,3,5‐triazine hybrids (2017–present): The anticancer activity, structure–activity relationships, and mechanisms of action" @default.
- W4308957608 cites W2000501946 @default.
- W4308957608 cites W2017236628 @default.
- W4308957608 cites W2586125932 @default.
- W4308957608 cites W2750423398 @default.
- W4308957608 cites W2765446427 @default.
- W4308957608 cites W2766455459 @default.
- W4308957608 cites W2766496146 @default.
- W4308957608 cites W2767600093 @default.
- W4308957608 cites W2768328571 @default.
- W4308957608 cites W2770746352 @default.
- W4308957608 cites W2787550429 @default.
- W4308957608 cites W2790443699 @default.
- W4308957608 cites W2794145005 @default.
- W4308957608 cites W2802738091 @default.
- W4308957608 cites W2810195079 @default.
- W4308957608 cites W2810221725 @default.
- W4308957608 cites W2824569982 @default.
- W4308957608 cites W2885126459 @default.
- W4308957608 cites W2888533602 @default.
- W4308957608 cites W2889004478 @default.
- W4308957608 cites W2892109824 @default.
- W4308957608 cites W2892277437 @default.
- W4308957608 cites W2895630774 @default.
- W4308957608 cites W2898036491 @default.
- W4308957608 cites W2898372019 @default.
- W4308957608 cites W2909339828 @default.
- W4308957608 cites W2920092350 @default.
- W4308957608 cites W2922727310 @default.
- W4308957608 cites W2923861405 @default.
- W4308957608 cites W2931130312 @default.
- W4308957608 cites W2939604347 @default.
- W4308957608 cites W2948610840 @default.
- W4308957608 cites W2951206054 @default.
- W4308957608 cites W2952139655 @default.
- W4308957608 cites W2955951604 @default.
- W4308957608 cites W2966626464 @default.
- W4308957608 cites W2967726326 @default.
- W4308957608 cites W2971886359 @default.
- W4308957608 cites W2987044260 @default.
- W4308957608 cites W2991303558 @default.
- W4308957608 cites W2992266871 @default.
- W4308957608 cites W2994870114 @default.
- W4308957608 cites W2996310127 @default.
- W4308957608 cites W2997784999 @default.
- W4308957608 cites W2997852254 @default.
- W4308957608 cites W3002485806 @default.
- W4308957608 cites W3009169840 @default.
- W4308957608 cites W3010888487 @default.
- W4308957608 cites W3011822251 @default.
- W4308957608 cites W3013038172 @default.
- W4308957608 cites W3016929082 @default.
- W4308957608 cites W3020555499 @default.
- W4308957608 cites W3021441437 @default.
- W4308957608 cites W3024890099 @default.
- W4308957608 cites W3025488782 @default.
- W4308957608 cites W3033552966 @default.
- W4308957608 cites W3036361505 @default.
- W4308957608 cites W3037768909 @default.
- W4308957608 cites W3038795160 @default.
- W4308957608 cites W3040634763 @default.
- W4308957608 cites W3041539627 @default.
- W4308957608 cites W3042679611 @default.
- W4308957608 cites W3043611847 @default.
- W4308957608 cites W3047197309 @default.
- W4308957608 cites W3082099753 @default.
- W4308957608 cites W3082763968 @default.
- W4308957608 cites W3083694960 @default.
- W4308957608 cites W3091980736 @default.
- W4308957608 cites W3093505939 @default.
- W4308957608 cites W3093820358 @default.
- W4308957608 cites W3097192651 @default.
- W4308957608 cites W3115429202 @default.
- W4308957608 cites W3115937790 @default.
- W4308957608 cites W3118512697 @default.
- W4308957608 cites W3120219008 @default.
- W4308957608 cites W3122634345 @default.
- W4308957608 cites W3124165020 @default.
- W4308957608 cites W3124510804 @default.
- W4308957608 cites W3128646645 @default.
- W4308957608 cites W3128712310 @default.
- W4308957608 cites W3131353099 @default.
- W4308957608 cites W3136533107 @default.
- W4308957608 cites W3141784901 @default.
- W4308957608 cites W3149826509 @default.
- W4308957608 cites W3171340099 @default.
- W4308957608 cites W3173697795 @default.
- W4308957608 cites W3175159661 @default.
- W4308957608 cites W3175474485 @default.
- W4308957608 cites W3177001566 @default.